Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bo Fu

Showing results (771-780 of 773) with videos related to

Pageof 78
Sort By:
You have reached the last page of results.This site can display upto 773 results.
The New England Journal of Medicine|January 25, 2018
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 InfectionStefan Zeuzem, Graham R Foster, Stanley Wang, et al.
The Lancet. Infectious Diseases|January 29, 2022
Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre studySaranya Sridhar, Arnel Joaquin, Matthew I Bonaparte, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 17, 2025
Risk factors associated with Helicobacter pylori infection in the urban population of China: A nationwide, multi-center, cross-sectional studyLiang Wang, Zheng-Kang Li, Jin-Xin Lai, et al.
Pageof 78

Showing results (771-780 of 773) with videos related to

Sort By:
Pageof 78
You have reached the last page of results.This site can display upto 773 results.
The New England Journal of Medicine|January 25, 2018
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 InfectionStefan Zeuzem, Graham R Foster, Stanley Wang, et al.
The Lancet. Infectious Diseases|January 29, 2022
Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre studySaranya Sridhar, Arnel Joaquin, Matthew I Bonaparte, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 17, 2025
Risk factors associated with Helicobacter pylori infection in the urban population of China: A nationwide, multi-center, cross-sectional studyLiang Wang, Zheng-Kang Li, Jin-Xin Lai, et al.
Pageof 78